Dual role of anti-TNF therapy enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues

Dual role of anti-TNF therapy : enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues

Copyright © 2011 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 139(2011), 2 vom: 15. Mai, Seite 164-76
1. Verfasser: Bosè, Francesca (VerfasserIn)
Weitere Verfasser: Raeli, Lorenzo, Garutti, Cecilia, Frigerio, Elena, Cozzi, Alessandra, Crimi, Marco, Caprioli, Flavio, Scavelli, Rossana, Altomare, Gianfranco, Geginat, Jens, Abrignani, Sergio, Reali, Eva
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2011
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial Journal Article Research Support, Non-U.S. Gov't Anti-Inflammatory Agents, Non-Steroidal Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antigens, CD Bacterial Toxins Cytokines Enterotoxins mehr... Immunoglobulin G Receptors, Antigen, T-Cell Receptors, Tumor Necrosis Factor Superantigens Tumor Necrosis Factor-alpha Viral Matrix Proteins enterotoxin F, Staphylococcal Infliximab B72HH48FLU Adalimumab FYS6T7F842 Etanercept OP401G7OJC
LEADER 01000naa a22002652 4500
001 NLM205995780
003 DE-627
005 20231223235008.0
007 cr uuu---uuuuu
008 231223s2011 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2011.01.015  |2 doi 
028 5 2 |a pubmed24n0687.xml 
035 |a (DE-627)NLM205995780 
035 |a (NLM)21334981 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Bosè, Francesca  |e verfasserin  |4 aut 
245 1 0 |a Dual role of anti-TNF therapy  |b enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues 
264 1 |c 2011 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 23.06.2011 
500 |a Date Revised 19.11.2015 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2011 Elsevier Inc. All rights reserved. 
520 |a The impact of anti-TNF therapy on systemic immune responses in patients has not been clearly defined. Here, we examined Th1/Th2/Th17 cytokine expression, activation and proliferation of peripheral T cells from patients with psoriasis and inflammatory bowel disease before and during anti-TNF therapy. In parallel, we calculated the correlation with the clinical response and we monitored cytokine expression in biopsies from inflamed tissues. We evidenced a dual role of TNF-blockade. In peripheral blood, it increased the expression of cytokines such as IL-17, IL-10, and IFN-γ, and enhanced the expression of activation markers and the proliferative response of CD4 T cells to TCR stimulation. By contrast, in biopsies from target tissues, TNF-blockade diminished the expression of Th17/Th1 cytokine and early inflammatory genes. Importantly, the enhanced T cell responses to TCR-stimulation did not impair the clinical response to the therapy and, in responder patients, occurred with the concomitant down-regulation of inflammatory genes in the target tissues 
650 4 |a Clinical Trial 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a Anti-Inflammatory Agents, Non-Steroidal  |2 NLM 
650 7 |a Antibodies, Monoclonal  |2 NLM 
650 7 |a Antibodies, Monoclonal, Humanized  |2 NLM 
650 7 |a Antigens, CD  |2 NLM 
650 7 |a Bacterial Toxins  |2 NLM 
650 7 |a Cytokines  |2 NLM 
650 7 |a Enterotoxins  |2 NLM 
650 7 |a Immunoglobulin G  |2 NLM 
650 7 |a Receptors, Antigen, T-Cell  |2 NLM 
650 7 |a Receptors, Tumor Necrosis Factor  |2 NLM 
650 7 |a Superantigens  |2 NLM 
650 7 |a Tumor Necrosis Factor-alpha  |2 NLM 
650 7 |a Viral Matrix Proteins  |2 NLM 
650 7 |a enterotoxin F, Staphylococcal  |2 NLM 
650 7 |a Infliximab  |2 NLM 
650 7 |a B72HH48FLU  |2 NLM 
650 7 |a Adalimumab  |2 NLM 
650 7 |a FYS6T7F842  |2 NLM 
650 7 |a Etanercept  |2 NLM 
650 7 |a OP401G7OJC  |2 NLM 
700 1 |a Raeli, Lorenzo  |e verfasserin  |4 aut 
700 1 |a Garutti, Cecilia  |e verfasserin  |4 aut 
700 1 |a Frigerio, Elena  |e verfasserin  |4 aut 
700 1 |a Cozzi, Alessandra  |e verfasserin  |4 aut 
700 1 |a Crimi, Marco  |e verfasserin  |4 aut 
700 1 |a Caprioli, Flavio  |e verfasserin  |4 aut 
700 1 |a Scavelli, Rossana  |e verfasserin  |4 aut 
700 1 |a Altomare, Gianfranco  |e verfasserin  |4 aut 
700 1 |a Geginat, Jens  |e verfasserin  |4 aut 
700 1 |a Abrignani, Sergio  |e verfasserin  |4 aut 
700 1 |a Reali, Eva  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 139(2011), 2 vom: 15. Mai, Seite 164-76  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:139  |g year:2011  |g number:2  |g day:15  |g month:05  |g pages:164-76 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2011.01.015  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 139  |j 2011  |e 2  |b 15  |c 05  |h 164-76